Amgen Inc
AMGN Real Time Price USD$AMGN stock is featured in our Claude - Quiver Enhanced, Dan Meuser, and Rob Bresnahan strategies.
All StrategiesRecent trades of AMGN by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in AMGN holdings by institutional investors
Quarterly net insider trading by AMGN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$80,000 Jul 20, 2026 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$2,440,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$50,000 Jul 20, 2026 Issue: Medicare/Medicaid
-
$60,000 Jul 20, 2026 Issue: Budget/Appropriations Labor Issues/Antitrust/Workplace Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$7,500 Jul 20, 2026 Issue: Health Issues
-
$50,000 Jul 20, 2026 Issue: Health Issues
-
$60,000 Jul 20, 2026 Issue: Immigration Health Issues Medicare/Medicaid
-
$60,000 Jul 19, 2026 Issue: Medicare/Medicaid Health Issues
-
$10,000 Jul 19, 2026 Issue: Health Issues
-
$50,000 Jul 19, 2026 Issue: Pharmacy
-
$60,000 Jul 17, 2026 Issue: Health Issues Budget/Appropriations
-
$60,000 Jul 16, 2026 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
-
$50,000 Jul 16, 2026 Issue: Medicare/Medicaid
-
$50,000 Jul 16, 2026 Issue: Health Issues
-
$37,500 Jul 10, 2026 Issue: Health Issues
-
$5,000 Jun 12, 2026 Issue: Health Issues
-
$10,000 Apr 22, 2026 Issue: Health Issues
-
$2,580,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$80,000 Apr 20, 2026 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$60,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
-
$50,000 Apr 20, 2026 Issue: Health Issues
-
$60,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Labor Issues/Antitrust/Workplace Copyright/Patent/Trademark
-
$60,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid Immigration
-
$50,000 Apr 18, 2026 Issue: Medicare/Medicaid
-
$50,000 Apr 18, 2026 Issue: Health Issues
-
$60,000 Apr 17, 2026 Issue: Medicare/Medicaid Health Issues
-
$7,500 Apr 17, 2026 Issue: Health Issues
-
$60,000 Apr 17, 2026 Issue: Health Issues Budget/Appropriations
-
$37,500 Apr 13, 2026 Issue: Health Issues
-
$50,000 Apr 09, 2026 Issue: Pharmacy
-
$80,000 Jan 20, 2026 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$60,000 Jan 20, 2026 Issue: Medicare/Medicaid Budget/Appropriations Health Issues
-
$60,000 Jan 20, 2026 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Labor Issues/Antitrust/Workplace Copyright/Patent/Trademark
-
$3,550,000 Jan 20, 2026 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$50,000 Jan 20, 2026 Issue: None
-
$60,000 Jan 20, 2026 Issue: Medicare/Medicaid Health Issues
-
$50,000 Jan 20, 2026 Issue: Health Issues
-
$60,000 Jan 20, 2026 Issue: Health Issues Medicare/Medicaid Immigration
-
$20,000 Jan 19, 2026 Issue: Health Issues
-
$50,000 Jan 19, 2026 Issue: Health Issues
-
$50,000 Jan 19, 2026 Issue: Pharmacy
-
$50,000 Jan 18, 2026 Issue: Medicare/Medicaid
-
$60,000 Jan 16, 2026 Issue: Health Issues Budget/Appropriations
-
$7,500 Jan 16, 2026 Issue: Health Issues
-
$37,500 Jan 12, 2026 Issue: Health Issues
-
$50,000 Oct 20, 2025 Issue: Pharmacy
-
$2,580,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$3,550,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$7,500 Oct 20, 2025 Issue: Health Issues
-
$60,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Labor Issues/Antitrust/Workplace Copyright/Patent/Trademark
-
$60,000 Oct 20, 2025 Issue: Health Issues Medicare/Medicaid Immigration
-
$50,000 Oct 20, 2025 Issue: Health Issues
-
$60,000 Oct 20, 2025 Issue: Health Issues Budget/Appropriations
-
$50,000 Oct 19, 2025 Issue: None
-
$60,000 Oct 19, 2025 Issue: Medicare/Medicaid Health Issues
-
$50,000 Oct 19, 2025 Issue: Health Issues
-
$50,000 Oct 17, 2025 Issue: Medicare/Medicaid
-
$60,000 Oct 15, 2025 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
-
$15,000 Oct 14, 2025 Issue: Health Issues
-
$37,500 Oct 14, 2025 Issue: Health Issues
-
$80,000 Oct 11, 2025 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$7,500 Sep 25, 2025 Issue: Health Issues
-
$50,000 Jul 21, 2025 Issue: Medicare/Medicaid
-
$50,000 Jul 21, 2025 Issue: Medicare/Medicaid
-
$15,000 Jul 21, 2025 Issue: Health Issues
-
$60,000 Jul 21, 2025 Issue: Medicare/Medicaid Immigration Health Issues
-
$50,000 Jul 21, 2025 Issue: Health Issues
-
$60,000 Jul 19, 2025 Issue: Medicare/Medicaid
-
$50,000 Jul 19, 2025 Issue: None
-
$80,000 Jul 19, 2025 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$50,000 Jul 18, 2025 Issue: Health Issues
-
$60,000 Jul 18, 2025 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Labor Issues/Antitrust/Workplace
-
$60,000 Jul 18, 2025 Issue: Health Issues Budget/Appropriations
-
$35,000 Jul 17, 2025 Issue: Health Issues
-
$60,000 Jul 16, 2025 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
-
$7,500 Jul 14, 2025 Issue: Health Issues
-
$60,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Immigration
-
$3,610,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$60,000 Apr 21, 2025 Issue: Health Issues Budget/Appropriations
-
$60,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Labor Issues/Antitrust/Workplace Copyright/Patent/Trademark
-
$50,000 Apr 21, 2025 Issue: Health Issues
-
$80,000 Apr 21, 2025 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$10,000 Apr 20, 2025 Issue: Health Issues
-
$60,000 Apr 18, 2025 Issue: Medicare/Medicaid
-
$50,000 Apr 18, 2025 Issue: Health Issues
-
$50,000 Apr 18, 2025 Issue: Medicare/Medicaid
-
$50,000 Apr 17, 2025 Issue: Medicare/Medicaid
-
$7,500 Apr 15, 2025 Issue: Health Issues
-
$60,000 Apr 15, 2025 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
-
$30,000 Apr 11, 2025 Issue: Health Issues
-
$2,980,000 Feb 04, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$60,000 Jan 22, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Labor Issues/Antitrust/Workplace Copyright/Patent/Trademark
-
$2,780,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$60,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Immigration
-
$60,000 Jan 21, 2025 Issue: Medicare/Medicaid Pharmacy
-
$50,000 Jan 20, 2025 Issue: Health Issues
-
$60,000 Jan 20, 2025 Issue: Health Issues
-
$20,000 Jan 20, 2025 Issue: Health Issues
-
$50,000 Jan 20, 2025 Issue: Medicare/Medicaid
-
$60,000 Jan 19, 2025 Issue: Medicare/Medicaid
Former government officials who have lobbied for AMGN
157 former government officials from 91 congressional offices at 36 lobbying firms have lobbied for AMGN, most recently Jul 20, 2026.
-
Paul Edattel House Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg -
Daniel Todd Senate Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Amin Ctr. Medicare & Medicaid
-
Eric Bergren House Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker -
Katherine Cotton House Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
-
Nicolas Magallanes House Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander -
Molly Fromm House New (continued) U.S. House Cmte on Oversight and Government Reform, Deputy General Counsel, Parliamentarian, Professional Staff Member; U.S. Rep. Darrell Issa, Leg. Asst., Leg. Corr., Staff Asst., Intern -
Christopher Wilcox House LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings -
Jeanne Haggerty Senate Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
AMGN Estimated quarterly lobbying spending
AMGN Revenue by Segment or Geography
New AMGN patent grants
-
Patent Title: Bcma antigen binding proteins Jan. 26, 2016
-
Patent Title: Aurora kinase modulators and method of use Jan. 26, 2016
-
Patent Title: Feed media Jan. 05, 2016
-
Patent Title: Pre-filled syringe identification tag Jan. 05, 2016
-
Patent Title: Bicyclic sulfonamide compounds as sodium channel inhibitors Dec. 15, 2015
-
Patent Title: Monomeric antibody fc Dec. 01, 2015
-
Patent Title: Specific binding agents of human angiopoietin-2 Dec. 01, 2015
-
Patent Title: Bicyclic pyridazine compounds as pim inhibitors Nov. 17, 2015
-
Patent Title: Ferroportin antibodies and methods of use Nov. 03, 2015
-
Patent Title: Heterobicyclic compounds Nov. 03, 2015
-
Patent Title: Apelin antigen-binding proteins and uses thereof Oct. 13, 2015
-
Patent Title: Predictive biomarker of survival in the treatment of renal cell carcinoma Oct. 06, 2015
-
Patent Title: Sclerostin antibody crystals and formulations thereof Sep. 29, 2015
-
Patent Title: Thrombopoietic compounds Sep. 29, 2015
-
Patent Title: Peptides and related molecules that bind to tall-1 Sep. 22, 2015
-
Patent Title: Method for culturing mammalian cells to improve recombinant protein production Sep. 15, 2015
-
Patent Title: Bispecific binding agents Sep. 15, 2015
-
Patent Title: Aurora kinase modulators and methods of use Sep. 08, 2015
-
Patent Title: Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase Aug. 25, 2015
-
Patent Title: Modified fc molecules Aug. 25, 2015
-
Patent Title: Human cgrp receptor binding proteins Aug. 11, 2015
-
Patent Title: Methods of selecting epidermal growth factor receptor (egfr) binding agents Aug. 04, 2015
-
Patent Title: Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof Aug. 04, 2015
-
Patent Title: Trpm8 antagonists and their use in treatments Aug. 04, 2015
-
Patent Title: Bicyclic compounds as pim inhibitors Jul. 28, 2015
-
Patent Title: Method for inhibiting bone resorption Jul. 28, 2015
-
Patent Title: Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use Jul. 21, 2015
-
Patent Title: Heteroaryl sodium channel inhibitors Jul. 14, 2015
-
Patent Title: Fused heterocyclic derivatives and methods of use Jun. 30, 2015
-
Patent Title: Drug delivery device Jun. 23, 2015
-
Patent Title: Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) Jun. 16, 2015
-
Patent Title: Sulfamide sodium channel inhibitors Jun. 09, 2015
-
Patent Title: Methods of using antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) Jun. 02, 2015
-
Patent Title: Crystalline polypeptides Apr. 21, 2015
-
Patent Title: Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use Apr. 21, 2015
-
Patent Title: Bicyclic aryl and heteroaryl sodium channel inhibitors Apr. 21, 2015
-
Patent Title: Dipeptides to enhance yield and viability from cell cultures Apr. 21, 2015
-
Patent Title: Modified lecithin-cholesterol acyltransferase enzymes Apr. 14, 2015
-
Patent Title: Variant activin receptor polypeptides and uses thereof Apr. 07, 2015
-
Patent Title: Antibodies that bind myostatin, compositions and methods Apr. 07, 2015
-
Patent Title: Carrier immunoglobulins and uses thereof Mar. 31, 2015
-
Patent Title: Rankl antibody-pth/pthrp chimeric molecules Mar. 31, 2015
-
Patent Title: Cd27l antigen binding proteins Mar. 24, 2015
-
Patent Title: Human anti-b7rp1 neutralizing antibodies Mar. 17, 2015
-
Patent Title: Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) Mar. 17, 2015
-
Patent Title: Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors Mar. 17, 2015
-
Patent Title: Pharmaceutical formulations Mar. 17, 2015
-
Patent Title: Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use Feb. 24, 2015
-
Patent Title: Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use Feb. 17, 2015
-
Patent Title: Unsaturated nitrogen heterocyclic compounds useful as pde10 inhibitors Feb. 17, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded to AMGN from public contracts
Recent insights relating to AMGN
Recent picks made for AMGN stock on CNBC
ETFs with the largest estimated holdings in AMGN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $AMGN stock a Buy, Sell, or Hold?
- What is the price target for $AMGN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $AMGN stock?
- Who owns the most shares of $AMGN stock?
- What funds own $AMGN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AMGN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
- Address Thousand Oaks, CA
- Market Cap 217.9 billion
- Employees 31,500
- Industrial Classification Biological Products, (No Diagnostic Substances)
Amgen Inc (AMGN) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Amgen Inc (AMGN).
Quiver Premium charts AMGN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at AMGN, per a recent SEC DEF 14A filing. We estimate that the median employee at AMGEN INC is paid $154,123.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|